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A B S T R A C T
Mutations in FARS2 are known to cause dysfunction of mitochondrial translation due to deﬁcient aminoacyla-
tion of the mitochondrial phenylalanine tRNA. Here, we report three novel mutations in FARS2 found in two
patients in a compound heterozygous state. The missense mutation c.1082C > T (p.Pro361Leu) was detected in
both patients. The mutations c.461C > T (p.Ala154Val) and c.521_523delTGG (p.Val174del) were each detected
in one patient. We report abnormal in vitro aminoacylation assays as a functional validation of the molecular
genetic ﬁndings. Based on the phenotypic data of previously reported subjects and the two subjects reported
here, we conclude that FARS2 deﬁciency can be associated with two phenotypes: (i) an epileptic phenotype, and
(ii) a spastic paraplegia phenotype.
1. Introduction
Mitochondria supply most of the energy in eukaryotic cells via
adenosine triphosphate (ATP) generated through the oxidative phos-
phorylation (OXPHOS) system located at the inner mitochondrial
membrane. The OXPHOS system consists of ﬁve complexes: complex I
(NADH:ubiquinone oxidoreductase), complex II (succinate:ubiquinone
oxidoreductase), complex III (ubiquinol:cytochrome c oxidoreductase),
complex IV (cytochrome c oxidase) and complex V (ATP synthase).
Most of the subunits constituting these complexes are encoded by nu-
clear DNA (nuDNA) and only a minority by mitochondrial DNA
(mtDNA). The OXPHOS subunits encoded by mtDNA are transcribed
and translated in the mitochondrial matrix. Not only the mRNAs for
those subunits but also the transfer RNAs (mt-tRNAs) and the ribosomal
RNAs (mt-rRNAs) are encoded by the mtDNA. For mitochondrial
transcription and translation a series of nuclear-encoded proteins are
also needed [1,2]. The latter are synthesized outside the mitochondria
and subsequently imported into the mitochondrial matrix. An im-
portant group among these proteins are the mitochondrial aminoacyl-
tRNA synthetases (mt-aaRSs) [3].
The mt-aaRSs are a well-described group of enzymes responsible for
charging the mitochondrially-encoded tRNAs with their cognate amino
acids. Defects in mt-aaRSs result in defective intramitochondrial
translation, aﬀecting the OXPHOS complexes containing mitochond-
rially-encoded subunits (complexes I, III, IV and V). The clinical im-
portance of these enzymes is highlighted by the fact that all mt-aaRSs
genes have now been associated with human diseases [3–7].
FARS2 encodes the mitochondrial phenylalanyl tRNA synthetase.
Pathogenic variants in FARS2 have been reported so far in eighteen
patients from nine diﬀerent families. According to earlier publications,
the reported patients had either (i) early-onset epileptic encephalo-
pathy [8–12], (ii) autosomal recessive hereditary spastic paraplegia
[13,14], or (iii) juvenile onset refractory epilepsy [15].
Here, we present the clinical, biochemical and radiological ﬁndings
in two unrelated patients, for whom pathogenic variants in the FARS2
gene have been detected. Based on their clinical and radiological data
new insights are gained into the phenotype of FARS2 deﬁciency.
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2. Methods
2.1. Ethic statement
This study was approved by institutional ethical boards. Informed
consent allowing further research was signed by the parents of the
patients.
2.2. Spectrophotometric analysis
The activities of citrate synthase and OXPHOS complexes I, II, II
+ III, III and IV were assayed by spectrophotometric analysis in mi-
tochondria as previously described [16–23].
2.3. Blue native polyacrylamide gel electrophoresis
Mitochondria were isolated from skeletal muscle specimens and
from cultured skin ﬁbroblasts. The OXPHOS complexes were separated
by Blue Native-Polyacrylamide Gel Electrophoresis (BN-PAGE) fol-
lowed by in-gel catalytic activity staining according to previously re-
ported methods [24].
2.4. Respirometry
Oxygen consumption rate in cultured skin ﬁbroblasts derived from
proband 1 was determined using a Seahorse XFp (Agilent). 35,000 cells
were seeded per cell plate well and cultured for 24 h in Optimem
medium (Thermo Fisher Scientiﬁc). Oxygen consumption rate was
measured in triplicates in standard Seahorse assay medium (Agilent)
supplemented with 10 mM glucose, 1 mM pyruvate and 2 mM gluta-
mine (Sigma). Cells were challenged with 4 μM oligomycin, 2 μM car-
bonyl cyanide 4-(triﬂuoromethoxy)-phenylhydrazone (FCCP) and
0.5 μM of a rotenone antimycin A mix (Agilent). Afterwards, the eight
well plates were collected for evaluation of protein content and citrate
synthase activity per well. In each well, cells were detached after
trypsinization. Protein content was assayed using Bradford reagent
followed by spectrophotometric analysis. Citrate synthase activity was
assayed using a method previously described by Srere, adjusted to a
smaller sample volume of 200 μL [22]. Protein concentrations and ci-
trate synthase activities were used for normalization. Spare respiratory
capacity was calculated as the diﬀerence between the maximal and the
basal oxygen consumption rate.
The oxygen consumption rate in cultured skin ﬁbroblasts from
proband 2 was determined on the Oxygraph2k using a modiﬁed SUIT
protocol as described with the sequential addition of malate, pyruvate,
digitonin, ADP, glutamate, succinate, CCCP, rotenone, antimycin A,
tetramethyl-p-phenylenediamine (TMPD) with ascorbate, and azide
[25]. Calculated parameters include acceptor control ratio (ADP-pyr-
uvate), glutamate increase ((glutamate-ADP)/glutamate), Q-junction
(succinate/glutamate), coupling ratio (succinate/CCCP), complex I (C-
CCP-rotenone) and complex IV (TMPD-azide). Results were compared
to those of 53 runs from 29 control ﬁbroblasts. Log transformation of
ADP + pyruvate, glutamate, succinate, CCCP rates are normally dis-
tributed and results are expressed in Z-scores.
2.5. Whole exome sequencing
For proband 1, whole exome sequencing (WES) was performed
using the ReliaPrep Large-Volume HT gDNA Isolation System DNA
extraction kit (Promega), the SureSelectXT Human All Exome v5
(Agilent Technologies) library capture kit and a HiSeq4000 sequencer
(Illumina) per standard manufacturer-recommended methods. For
proband 2, WES trio sequencing with both biological parents was per-
formed. The DNA extraction, library preparation, DNA sequencing,
variant annotation and ﬁltering were performed using previously
published techniques by a commercial laboratory [26].
2.6. Mutation mapping
The locations of the three mutations were mapped on the crystal
structure of human mitochondrial phenylalanyl-tRNA synthetase
(FARS2) complexed with tRNAPhe (PDB ID: 3TUP) using the program
RasTop 2.2 (available at http://www.geneinﬁnity.org/rastop/, ac-
cessed on 7–11-17). Protein structure is shown as grey ribbon, mutation
sites as red spheres, and functionally important residues as blue sticks
[27]. Complexed tRNAPhe is shown as orange ball-and-stick.
2.7. Western blot analysis
Western blot analysis was performed in mitochondrial fractions
isolated from skeletal muscle. A commercial antibody against FARS2
was obtained from Proteintech Group (AB_2102499). Detection was
performed by chemiluminescence (Pierce ECL plus, Thermo Fisher
Scientiﬁc) per the manufacturer's instructions. Visualization was
achieved using the Celvin SnapAndGo software (Biostep GmbH). The
assembly of complex I was analyzed by western blotting following blue
native PAGE (5–13%) of an isolated mitochondrial membrane fraction
and probing with an antibody against NDUFS2, a component of the
earliest complex I assembly intermediate, and compared to the results
of 35 control ﬁbroblasts, in which only a minor band at 230 kDa
(< 13% of holocomplex) was observed [25].
2.8. Visualization of aminoacylation of four mitochondrial tRNA's
Analysis of aminoacylation status of mt-tRNAs was performed as
described before [28]. RNA from patient cell lines was extracted using
Trizol reagent following the manufacturer's instructions (Thermo Fisher
Scientiﬁc). The ﬁnal pellet was resuspended in 10 mM NaOAc (pH 5.0)
and kept at 4 °C to preserve the aminoacylation state. For the deacy-
lated control, the pellet was resuspended in 200 mM Tris-HCl at pH 9.5
and incubated at 75 °C for 5 min, followed by RNA precipitation and
resuspension in 10 mM NaOAc (pH 5.0). RNA samples (5 μg) were
mixed with an equal volume of sample buﬀer (0.1 M NaOAc pH 5.0,
8 M urea, 0.05% bromophenol blue, 0.05% xylene cyanol) and sepa-
rated by PAGE (6.5%, vol/vol; 8 M urea in 0.1 M NaOAc pH 5.0 at
4 °C). RNA was blotted onto a nylon transfer membrane (Hybond, GE
Healthcare). Membranes were hybridized with radioactive probes cor-
responding to the mt-tRNAs overnight at 65 °C in 7% SDS and 0.25 M
sodium phosphate buﬀer (pH 7.6), washed with 1× SSC (150 mM so-
dium chloride and 15 mM sodium citrate, pH 7.0) three times for
20 min and then three times with 1× SSC containing 0.1% SDS
(20 min; 65 °C), exposed to a storage phosphor screen (GE Healthcare),
visualized in a Typhoon phosphorimaging system and quantiﬁed using
ImageQuant software (Molecular Dynamics, GE Healthcare) or ImageJ
(http://imagej.nih.gov/ij).
2.9. Mitochondrial translation assay
Metabolic labelling of mtDNA-encoded proteins in cultured skin
ﬁbroblasts was performed essentially as described previously [29].
Brieﬂy, prior to metabolic labelling cells were cultured to 80% con-
ﬂuency in 6 well-plates in DMEM, supplemented with 10% standard
FBS, 2 mM Glutamax and 110 mg/L sodium pyruvate. The medium was
removed and the cells were washed twice in methionine/cysteine free
DMEM, then left to incubate for 20 min at 37 °C in methionine/cysteine
free DMEM supplemented with 2 mM Glutamax, 110 mg/L sodium
pyruvate, 96 μg/mL cysteine and 5% dialyzed serum. To inhibit cyto-
solic translation, emetine dihydrochloride was then added to a ﬁnal
concentration of 100 μg/mL for 30 min. This allowed for speciﬁc la-
belling of mitochondrial translation products following addition of
100 μCi [35S]-L-methionine and incubation at 37 °C. After 30 min, the
labelling medium was removed and cells were collected via pipetting
and pelleted by centrifugation at 500g for 5 min. Protein lysate was
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resolved via SDS-PAGE, dried and imaged as described above.
3. Case histories and results
3.1. Proband 1
Proband 1 is the ﬁrst-born child of healthy non-consanguineous
parents. He was born at term after an uneventful pregnancy. He initially
presented with poor head control at age six months. At 13 months, he
could brieﬂy sit independently. He was noted to have frequent emesis.
At 15 months, he started having startle reactions followed by staring
and clonic movements of the arms and legs. The echocardiogram and
retinal examination were normal. Lactate in serum was increased on
multiple measurements (5.1–6.4 mmol/L, normal < 2.22). Organic
acid proﬁle in urine showed an increase of lactate (16 mmol/L,
normal < 4.4), pyruvate (7 mmol/L, normal < 1.1), alpha-keto-glu-
tarate (62 mmol/L, normal < 0.7), succinate (13 mmol/L, normal <
2.6), fumarate (2.6 mmol/L, normal < 0.9) and glutarate (1.9 mmol/
L, normal < 0.4 mmol/L). The amino acid proﬁle in plasma showed an
increased concentration of alanine (688 μmol/L, normal 173–440).
Lactate concentration in CSF was increased (3.7 mmol/L, normal
0.9–1.9).
At the age of 19 months, he developed convulsive seizures.
Carbamazepine was started as anti-epileptic treatment and in the fol-
lowing ﬁve months seizures did not recur. Developmentally, he never
used words to communicate and lost the ability to sit without support.
Clinical examination revealed lower extremity hyperreﬂexia at that
time. Brain MRI at 20 months showed slight cortical atrophy.
At 27 months, he was admitted to hospital because of weight loss
and repeated vomiting. At that time, he only had minimal head control.
He also suﬀered from severe constipation and recurrent abdominal
pain. After the age of 2 ½ years, seizures stopped except for startle
myoclonus.
At eight years, he could use a wheelchair independently for mobi-
lity. He had recurrent pulmonary infections due to poor airway clear-
ance. He developed progressive kyphoscoliosis and progressive spasti-
city of the lower extremities.
At 13 years, he was seen by a urologist because of bilateral cryp-
torchidism for which orchidopexy was performed. He was also diag-
nosed with a neurogenic bladder and sphincter dyssynergia.
Anticholinergic medication and intermittent catheterization were
started.
At age 17 years, he lost the ability to use the wheelchair in-
dependently. Increasing problems with chewing and swallowing and
progressively more apneic episodes were noticed. Brain MRI showed
bilateral, round, focal T2-hyperintense lesions in the anterior part of the
mesencephalon (frontopontine pyramidal tracts) (Fig. 1B). He under-
went posterior spinal fusion for progressive scoliosis.
3.2. Proband 2
Patient 2 is a now 15-year-old female. She was born at 36 weeks
gestation and was small for gestational age with a birth weight of
1928 g. Bilateral talipes equinovarus was noticed at birth and there was
poor feeding in the neonatal period. Early gross motor milestones were
delayed with achievement of independent sitting at ten months and
crawling at 24 months. At 17 months, brain MRI showed symmetrical
T2 hyperintensities of the posterior tegmentum. By the age of 3
½ years, she could ambulate using a walker. At the age of six years,
signs of developmental regression were noticed after an acute re-
spiratory viral infection with loss of ambulation and development of
urinary incontinence. The regression signiﬁcantly aﬀected expressive
and receptive language. She also developed severe insomnia. Repeat
brain MRI at that time showed more extensive T2 hyperintense lesions
at the tegmentum and periaqueductal grey matter (Fig. 1E). She never
regained the ability to ambulate and used an electric wheelchair for
mobility after that time. She developed severe lower extremity spasti-
city and required femoral derotational osteotomies as well as Achilles
tenotomies for management of spasticity.
At age 15 years, bradykinesia and tremor were noticed, as well as
dystonic movements but no dysmetria nor ataxia. She could commu-
nicate with short phrases but with very slow and dysarthric speech.
Clinically apparent seizures were never seen. MRI of the brain at age
15 years showed near resolution of the tegmental lesions but new T2
hyperintense lesions bilaterally in the anterior inferior thalamus and
signs of cerebellar atrophy (Fig. 1F). Her diagnostic evaluation was
signiﬁcant for mild increase of lactate in serum and CSF (respectively
2.5 mmol/L and 2.9 mmol/L, normal < 2.0) and an increase of alanine
in serum (762 nmol/L, normal < 547) and CSF (40 nmol/L,
normal < 37). Pyruvic acid in CSF was 0.2 mmol/L (normal < 0.20)
and 0.2 mmol/L in serum (normal < 0.17).
3.3. Biochemical and molecular studies
For proband 1, light microscopic examination of a skeletal muscle
biopsy (M. quadriceps femoris) showed excessive neutral fat in muscle
ﬁbers which made interpretation of the spectrophotometric and the
microscopic analysis impossible. In cultured skin ﬁbroblasts, deﬁcient
Fig. 1. MRI studies.
Brain MRI studies of proband 1 (A–C) and proband 2 (D–F). Brain MRI of proband 1 at
19 years of age showing diﬀuse brain atrophy (A) and T2-hyperintense lesions in the
anterior medial part of the mesencephalon (B). MRI of the spinal cord of proband 1 at
14 years (C). Brain MRI of proband 2 at 15 years of age showing small lesions bilaterally
in the inferior thalamic region (D). Brain MRI at 6 years with T2-hyperintense lesions of
the tegmentum and the periaqueductal grey matter (E), and mild cerebellar atrophy (F).
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activity of complex IV was detected (complex I not measured). During
surgery, new skeletal muscle (M. semispinalis thoracis) and skin biopsies
were taken. Spectrophotometric analysis of the second muscle biopsy
showed isolated complex IV deﬁciency, and also in the new cultured
skin ﬁbroblasts (Table 1), conﬁrmed by BN-PAGE followed by in-gel
activity staining (Fig. 2). Determination of oxygen consumption rate
(OCR) in cultured skin ﬁbroblasts showed a severe decrease of the spare
respiratory capacity when compared to controls (Fig. 3).
mtDNA copy number and mtDNA deletions were analyzed in leu-
kocytes and both were normal. Complete mitochondrial genome se-
quencing did not reveal a pathogenic variant. Therefore, WES was
performed. Two missense variants were detected in FARS2
(NM_006567.4): one in exon 2 (c.461C > T; p.Ala154Val) and one in
exon 6 (c.1082C > T; p.Pro361Leu). These missense mutations were
considered likely pathogenic by several in silico prediction tools
(Sorting Intolerant From Tolerant [SIFT], MutationTaster, and
PolyPhen-2). Heterozygous variants Ala154Val and Pro361Leu occur
rarely in the population with a prevalence of 2/60,594 and 15/60,675
individuals (ExAC), respectively [30]. The two variants were conﬁrmed
to be in trans using targeted Sanger sequencing of the relevant DNA
fragment in the parents. Western blot analysis in skeletal muscle re-
vealed a similar amount of FARS2 protein in proband 1 when compared
to two controls (data not shown).
For proband 2, a surgical muscle biopsy of the M. quadriceps femoris
showed normal histological characteristics, normal mitochondrial ul-
trastructure on electron microscopy and normal staining for cyto-
chrome c oxidase activity. OXPHOS complex activity in skeletal muscle
was within normal limits for complexes I, II, III and IV (Table 1). BN-
PAGE followed by in-gel activity staining showed normal assembly of
complexes I, II, IV and V (III not assayed). Catalytic staining for
Table 1
OXPHOS spectrophotometric analyses.
Proband Tissue Complex I/CS Complex II/CS Complex II + III/CS Complex III/CS Complex IV/CS Citrate synthase
Proband 1 Skeletal muscle 67 [−1.69] 149 [−0.14] 128 [−0.78] 260 [−1.71] 337 [−3.10] 347
Controls (n= 30) 170 ± 47 197 ± 40 200 ± 46 598 ± 204 1008 ± 287 174 ± 70
Proband 1 Cultured skin ﬁbroblasts ND 116 [−1.68] 168 [−0.75] 495 [−0.29] 352 [−3.80] 94
Controls (n= 30) ND 189 ± 45 233 ± 71 586 ± 165 847 ± 169 82 ± 15
Proband 2 Skeletal muscle 168 [−0.42] 386 [0.23] 330 [0.05] 88 [0.44] 21 [1.23] 183
Controls (n= 22) 178 ± 52 357 ± 131 276 ± 108 70 ± 49 11 ± 6 257 ± 69
Proband 2 Cultured skin ﬁbroblasts 131 [−2.04] 682 [0.54] 412 [1.51] 59 [1.13] 8 [−1.27] 346
Controls (n= 32) 229 ± 75 595 ± 175 248 ± 85 39 ± 21 12 ± 5 407 ± 112
Data are expressed as the OXPHOS activity over citrate synthase activity. Between brackets is the Z-score based on the logarithm of OXPHOS activity divided by the logarithm of citrate
synthase activity. Control sample ratios are given as mean ± SD. Z-scores lower than− 1.96 are signiﬁcantly diﬀerent (P < 0.05) from the control samples and are considered to be
deﬁcient activities. Deﬁcient activities are shown in bold. ND: not determined. Citrate synthase activity expressed as nanomoles of substrate per minute per milligram of protein.
Fig. 2. In-gel activity staining of OXPHOS complexes.
In-gel activity staining of complexes I, II, IV and V in cul-
tured skin ﬁbroblasts and skeletal muscle of proband 1 (P1)
and 2 (P2) compared to controls (C1-4). In cultured skin
ﬁbroblasts and skeletal muscle from proband 1 complex IV
staining is deﬁcient. In cultured skin ﬁbroblasts from pro-
band 2, complex I and complex IV staining are slightly
decreased, while complexes V and II staining are compar-
able with the control staining. In skeletal muscle from
proband 2, complex IV staining is slightly decreased, while
the staining of complex I, V and II are comparable with the
control staining.
Fig. 3. Oxygen consumption study.
Oxygen consumption rate (OCR) was evaluated in cultured
skin ﬁbroblasts from proband 1 and compared to an intra-
run control. OCR was normalized over citrate synthase ac-
tivity (CS). Cultured skin ﬁbroblasts of proband 1 showed a
signiﬁcant decrease of oxygen consumption as compared to
the control during the entire run (A). The spare respiratory
capacity, calculated by subtracting the basal OCR from the
maximal OCR (third measurement after addition of FCCP),
is signiﬁcantly diﬀerent between the proband 1
(0.21 ± 0.03) and intra-run control (1.34 ± 0.12) (B).
The spare respiratory capacity is also signiﬁcantly de-
creased in cultured skin ﬁbroblasts of proband 1 when
compared to a small set of inter-run controls (n = 10,
1.17 ± 0.33).
E. Vantroys et al. Molecular Genetics and Metabolism 122 (2017) 172–181
175
complex IV was slightly decreased (Fig. 2). Spectrophotometric analysis
in cultured skin ﬁbroblasts revealed low activity of complex I. BN-PAGE
followed by in-gel activity staining in cultured ﬁbroblasts showed
slightly decreased staining for complex I and IV. Complexes II and V
were normal (Table 1, Fig. 2).
Trio WES was performed which showed compound heterozygosity
for two variants in the FARS2 gene (NM_006567.4): c.521_523delTGG;
p.Val174del and c.1082C > T; p.Pro361Ile. The Pro361Leu variant was
also found in proband 1 and Val174del is absent from ExAC [30]. The
locations of the missense mutations were mapped on the published
crystal structure [27]. The amino acids Ala154 and Val174 were located
in the catalytic module whereas Pro361 was located in the anticodon-
binding domain.
In the ﬁbroblasts of proband 2, the oxygen consumption showed a
reduced rate with pyruvate after stimulation with ADP, with glutamate,
and with succinate, but low normal after uncoupling with CCCP. The
calculated complex I rate was low, and the Q-point (S/G) was increased,
a constellation that is typical of primarily functional complex 1 deﬁ-
ciency (Table 2) ([25] and Van Hove and Friederich unpublished).
3.4. Functional studies
Functional impact of the detected FARS2 variants was tested by
high-resolution northern blotting of RNA isolated from cultured skin
ﬁbroblasts from proband 1 and 2, allowing distinction between the
aminoacyl-tRNA and the uncharged tRNA (Fig. 4). Using this approach,
we consistently detected a decreased ratio between aminoacylated (aa-)
and deacylated form of mitochondrial (mt-) tRNAPhe, while aminoa-
cylation of control mt-tRNAs (mt-tRNASer (UCN), mt-tRNASer (AGY),
tRNAGln and tRNAPro) was normal (Fig. 4). A stronger mt-tRNAPhe
aminoacylation defect was observed for the proband 2. To verify
whether the observed reduced availability of aa-mt-tRNAPhe resulted in
impairment of the mitochondrial translation rate, mtDNA-encoded
polypeptides were labeled using 35S-L-methionine upon inhibition of
cytoplasmic protein synthesis. A considerable decrease of translation of
mitochondrially-encoded polypeptides was detected in primary ﬁbro-
blasts from probands 1 and 2 (Fig. 5). The defect in mitochondrial
protein synthesis rate was, for some of the subunits, stronger in proband
2, consistent with a more pronounced defect in aminoacylation of mt-
tRNAPhe. The defect in synthesis rate was not general for all subunits of
the same complex, e.g. for complex I a decreased synthesis of ND6 can
be seen, while ND3 synthesis is comparable to controls.
To investigate if the decreased translation rate of mitochondrial
encoded subunits impaired the assembly of mitochondrial complexes,
Table 2
Oxygen consumption of ﬁbroblasts from proband 2 in a SUIT protocol.
Parameter Patient Median 5th and 95th percentile
Pyruvate + ADP 12.84 (z =−2.07) ↓ 28.6 14.2–63.1
Glutamate 12.98 (z =−2.28) ↓ 30.7 15.1–65.4
Succinate 22.93 (z =−1.85) ↓ 39.3 23.0–80.3
CCCP 50.21 (z =−1.07) 66.1 45.9–139.5
Acceptor control ratio 2.33 (z =−0.13) 2.37 1.22–4.42
Glutamate increase 0.01 (z =−1.85) ↓ 0.08 0.01–0.13
Qpoint 1.77 ↑ 1.28 1.13–1.67
Coupling ratio 0.46 (z =−1.19) 0.61 0.34–0.83
Complex 1 26.19 ↓ 48.4 31.6–123.2
Complex 4 61.50 52.3 30.8–108.2
The oxygen consumption by ﬁbroblasts from proband 2 was evaluated in a SUIT protocol
as described. Results are expressed in nmol oxygen consumed per minute and per 106
cells. Following the median value, the calculated Z-factor is given for the variable without
log transformation (glutamate increase and coupling ratio) and after log transformation
(ADP + pyruvate, Glutamate, succinate, CCCP, acceptor control ratio) using mean and
standard deviation derived from 53 runs of 29 control ﬁbroblasts, which showed nor-
mality of distribution for that parameter.
Fig. 4. Aminoacylation status of mitochondrial tRNAs.
Northern blot analysis of mitochondrial tRNA aminoacylation in
total RNA samples from proband 1 (P1) and 2 (P2), and control
ﬁbroblasts (C1, C2). Membranes were hybridized with radio-
active mt-tRNA probes as indicated. “dAc” indicates deacylated
control sample. Densitometric analysis of the northern blot hy-
bridized with mt-tRNA Phe shows a decrease of the ratio be-
tween aminoacylated (aa-) and deacylated form, as compared to
controls. This decrease is more distinct in proband 2. A slight
diﬀerence in the migration of the two mt-tRNASer products is
also seen in proband 2.
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complex I assembly was evaluated in ﬁbroblasts from proband 2 using
an antibody against the subunit NDUFS2, which is present from the
earliest subcomplexes. In normal control ﬁbroblasts, this subcomplex
was visible in 60% of cases at 7.15 ± 3.50%, maximum 13% of the
fully assembled complex. In proband 2, there was an increased amount
18–28% of the subcomplex at 230 kDa (Fig. 6). The 230 kDa sub-
complex is the point at which the ﬁrst mitochondrial DNA encoded
subunit ND1 is added to the growing complex and an increase in the
230 kDa subcomplex is observed in other defects of mitochondrial DNA
translation (Friederich and Van Hove, unpublished observations).
4. Discussion
In previous publications, patients with FARS2 deﬁciency were noted
to have either (i) early-onset epileptic encephalopathy [8–12], (ii) au-
tosomal recessive hereditary spastic paraplegia [13,14], or (iii) juvenile
onset refractory epilepsy [15]. Here, we report two FARS2 patients with
predominantly a spastic paraplegia. When looking at the phenotypes of
previously reported subjects and the two subjects reported here, we
propose to deﬁne the phenotypes not based on the age of onset but
rather on the predominant clinical ﬁndings, i.e. (i) an epileptic phe-
notype, and (ii) a spastic paraplegia phenotype, as shown in Table 3.
The epileptic phenotype of FARS2 deﬁciency is the most severe
phenotype. Delayed motor development is seen in the ﬁrst six months of
life. All of them (12/12) suﬀered from epilepsy, in most of them starting
in the ﬁrst years of life. Brain MRI was abnormal in all the subjects in
whom MRI was performed (9/9) and showed a wide range of ab-
normalities including diﬀuse brain atrophy, cerebral cortical atrophy,
thin corpus callosum, atrophic cerebellum, lesions in dentate nuclei and
mesencephalon, as well as signal abnormalities in putamen, caudate
nucleus and white matter. More than half of the subjects (7/12) with
the severe phenotype died before the age of two years. The spastic
paraplegia phenotype is less severe. It was ﬁrst reported in four siblings
born from consanguineous parents [14]. The two siblings reported here
can also be classiﬁed as having the spastic paraplegia phenotype. Pro-
band 1 suﬀered from mild seizures between the age of 15 and
30 months but afterwards his clinical picture was dominated by spastic
paraplegia. Proband 2 also had spastic paraplegia, no seizures. Also, the
two subjects reported by Vernon et al. [13] can be categorized into the
spastic paraplegia phenotype. One of them was a 5-year-old girl who
had only one seizure at the age of two months and afterwards was
found to have spastic paraplegia. Her older brother had neurological
complications in the neonatal period accompanied by seizures. Later, he
did not present anymore with seizures but underwent dorsal rhizotomy
surgery at the age ﬁve years which is a surgical procedure typically
performed for spastic paraplegia/tetraplegia.
The neuroradiological ﬁndings in proband 1 were unusual. Cerebral
MRI showed prominent round signal abnormalities bilaterally in the
most anterior parts of the mesencephalon. Only one other subject was
reported in the literature with similar lesions; that subject had ECHS1
deﬁciency [31]. Brain MRI in proband 2 showed signal abnormalities in
the posterior part of the mesencephalon around the aqueduct, a well-
described ﬁnding in patients with mitochondrial disease [32].
In the probands presented here, there was a long delay in de-
termination of the molecular genetic diagnosis despite the early char-
acteristic features of mitochondrial disease. The regression in both
probands and the increased lactate concentrations in serum, urine and
CSF, as well as the increased concentrations of alanine in serum and the
increase of Krebs cycle intermediates in urine was highly suggestive of a
mitochondrial defect. It was only after the use of WES that we could
pinpoint the underlying molecular defect. In the future, more subjects
with a FARS2 defect will likely be detected as WES continues to be more
frequently used as diagnostic tool in the clinical setting.
WES identiﬁed compound heterozygotes for missense mutations in
the two probands described here. Both probands are compound het-
erozygous for a mutation in the anticodon binding domain (Pro361Leu)
and one in the catalytic domain (Ala154Val and Val174del) conﬁrming
the association of both the catalytic and anticodon binding domain with
a severe phenotype. Most of the pathogenic variants reported in
Fig. 5. Mitochondrial translation.
Mitochondrial translation in the FARS2 probands. Mitochondrial protein synthesis in
cultured skin ﬁbroblasts from proband 1 (P1) and 2 (P2), and controls (C12), was ana-
lyzed by [35S]-L-methionine pulse labelling upon inhibition of cytosolic translation by
emetine. The products were resolved in SDS PAGE gel and subjected to autoradiography.
mtDNA-encoded structural subunits of complex I (ND1, ND2, ND3, ND4, ND4L, ND5,
ND6), complex III (CYTB), complex IV (MT-CO1, MT-CO2, MT-CO3), and complex V
(ATP6, ATP8) are shown. A defect in mitochondrial protein synthesis rate is seen in both
probands, with a more pronounced defect in proband 2 for some subunits (ND2, ATP6).
Coomassie blue stained gel (CBS) as loading control is shown at the bottom of the picture.
Fig. 6. Assembly of complex I.
The assembly of complex I is followed by Western blot using an antibody against
NDUFS2, a component of the earliest subcomplex loading 10 and 30 μg mitochondrial
membrane protein respectively. In proband 2 (P2), increased amounts are noted of the
subcomplex at 230 kDa and less at 400 kDa, whereas in the control cells (C1) only a very
faint band at 230 kDa is visible. This indicates a pathological slowing of the assembly of
complex I in proband 2.
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literature are in exon 2 of the FARS2 gene (6/13) and some in exon 5
and 6 (3/13 in each) (Fig. 7). Only one pathogenic variant was reported
in exon 7. FARS2 protein consists of 4 domains: the N-terminal region
(residues 36–83), the catalytic domain (residues 84–325), the linker
region (residues 326–358) and the anticodon binding domain (residues
359–451) [33]. No clear link can be detected between the domain af-
fected by the mutation and phenotype. Most mutations are in the cat-
alytic domain and homozygous mutations in this domain can cause
both the epileptic (Tyr144Cys) as the spastic paraplegia phenotype
(Asp142Tyr). The epileptic phenotype has also been described with
mutations in the catalytic domain, anticodon binding domain and
linker region. So far, no mutations have been reported in the N-terminal
region.
Molecular modeling showed the locations of Ala154, Val174 and
Pro361 mapped on the crystal structure of human mitochondrial phe-
nylalanyl-tRNA synthetase FARS2 complexed with tRNAPhe (PDB ID:
3TUP) (Fig. 8). Two of the mutations sites (Ala154 and Val174) are
located near the active site in the catalytic module (CAM) of FARS2
protein. Ala154 is located in the active site pocket. The valine mutation
at this site could potentially change the shape of the pocket resulting in
the inability of substrate phenylalanine from interacting with Phe268
and Phe270, which are responsible for substrate recognition [27].
Val174 is located in a β-sheet adjacent to the active site Glu195 which
participates in hydrogen bonding with the phenylalanine substrate and
transition state intermediates through a coordinated water molecule
[27]. The amino nitrogen of Val174 is 5.18 Å from the carbonyl oxygen
of Glu195. An alanine substitution at this position could result a change
in the orientation of the Glu195 and the inability to properly coordinate
the phenylalanine substrate in the active site. Pro361 is located in the
anticodon binding domain (ABD) of the FARS2 protein and is right next
to Tyr360 which participates in hydrogen bonding interactions with
Glu394 and Arg419. The Arg419 residue has been described as shape-
generating for the ABD and the interactions with Tyr360 and Glu394
are important for the structural stabilization of the ADB [27]. The
Pro361Leu mutation could lead to a structural change that breaks the
hydrogen bond between Tyr360 and Arg419 which would aﬀect the
stability of the ABD leading to decreased interaction with the tRNAPhe.
Although the amino acids involved are conserved and in silico
programs predict pathogenicity, and molecular modeling suggests that
mutating these amino acids may aﬀect enzymatic function, direct
functional testing is required to conﬁrm the pathogenicity of the ﬁnd-
ings. FARS2 catalyzes the charging of the tRNAPhe, and in the two
probands presented here we demonstrated a decreased amount of Phe-
charged tRNA and an increased amount of deacylated tRNA for phe-
nylalanine. We next documented that this reduced charging aﬀected
mitochondrial translation in a direct assay using labeled methionine.
Next we evaluated whether the decreased mitochondrial translation
aﬀected the assembly of the OXPHOS complexes, and documented
abnormal assembly intermediates of complex I.
Microscopic and histochemical examination of skeletal muscle in-
itially did not reveal abnormalities suggestive of a mitochondrial defect
in proband 1 and proband 2 (no ragged-red ﬁbers, no COX negative
ﬁbers). This was also the case in previously reported subjects with
FARS2 deﬁciency [8,15]. In proband 1, biochemical investigations in
skeletal muscle and in cultured skin ﬁbroblasts revealed a complex IV
deﬁciency. In proband 2, OXPHOS complex activities were normal in
skeletal muscle, while a complex I deﬁciency was found in cultured skin
ﬁbroblasts. This is peculiar since skeletal muscle is usually more af-
fected than cultured skin ﬁbroblasts. These results suggest that the
skeletal muscle is less aﬀected in proband 2 which correlates well with
the clinical ﬁndings. Proband 2 ambulated until the age of six years
while proband 1 never gained the ability to walk independently. In
previously reported FARS2 deﬁcient subjects, biochemical studies are
scarce. Biochemical investigations in skeletal muscle were reported in
only three subjects. In two of them an isolated complex IV deﬁciency
was found and in one a normal activity of the OXPHOS complexes I toTa
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IV [9,10,15]. Biochemical investigations in cultured skin ﬁbroblasts
were reported in only three subjects. In two of them, the OXPHOS ac-
tivities were normal and in the other a decrease of the activities of
complex I and IV was detected [9–11]. The conclusion is that the OX-
PHOS defects detected in FARS2 deﬁcient subjects vary from normal, to
isolated complex IV deﬁciency, isolated complex I deﬁciency, or to a
combined complex I + IV deﬁciency. The variable involvement of
intra-mitochondrial translation preferentially aﬀects complexes I and
IV, as these are the two complexes that are composed of the largest
number of mitochondrially-encoded subunits.
Abnormal subcomplexes of complex V are expected to be seen in
mitochondrial translation defects when using Blue Native PAGE. They
were not seen in either proband in this report, indicating that there is
still enough translation of the two complex V subunits. On oxygen
consumptions studies, proband 1 had a decrease in the spare respiratory
capacity. Proband 2 had decreased complex 1 activity and increased Q-
point (succinate/glutamate ratio), indicative of reduced eﬀective
complex I rate. The variable enzymatic test results in the patients with
FARS2 deﬁciency highlight the diﬃculties in recognizing the mi-
tochondrial dysfunction using traditional enzymatic methods in cul-
tured skin ﬁbroblasts. In known patients with mitochondrial disorders,
ﬁbroblasts only detect an enzymatic deﬁciency in half of the patients
[34], illustrating the need for more targeted testing. As shown here,
targeted functional testing based on the identiﬁed genetic defect of
tRNA charging, mitochondrial translation and complex I assembly
could clearly identify functional defects, even in ﬁbroblasts. This case
illustrates the complementary nature of broad molecular genetic testing
and targeted functional analysis of mitochondrial enzymes in the di-
agnostic evaluation of the patients with suspected mitochondrial dis-
ease, even when using ﬁbroblasts as tissue for functional analysis,
which can be obtained from a minimally invasive skin biopsy.
In conclusion, we report two patients with three diﬀerent mutations
in FARS2 as well as indirect functional evidence of likely pathogenicity
of the mutations. Both subjects had spastic paraplegia and can be added
to the group of patients with predominantly spastic paraplegia. We can
conclude that FARS2 deﬁcient subjects can be categorized into either an
epileptic phenotype or a spastic paraplegia phenotype.
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